Now among India’s top fully accredited diagnostic chains

Mumbai, India, April 23, 2025: Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin) has achieved 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation across all its greenfield labs.

“This accreditation is a testament to the team’s dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics,” said Ravindra Kumar, CEO, Lupin Diagnostics. “We remain committed to enhancing healthcare through continuous improvement and innovation.”

This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services. The company’s commitment to quality is reflected in every aspect of its operations, ensuring patients receive accurate and timely results that they can trust.

Among its recent accolades, Lupin Diagnostics received the prestigious titles of ‘Patient-Centric Diagnostic Laboratories Company of the Year’ at the IHW 3rd Patients First Award 2024, ‘Emerging Diagnostics Chain of the Year’ at the Diagnostics Innovation and Excellence Award 2024 by Voice of Healthcare, and ‘Pathology Lab of the Year’ (National Category) at the ET Healthcare Awards in 2022 and 2024. These honors emphasize the company’s dedication to patient-centered care and its leading position in the diagnostics industry.

About Lupin Diagnostics
Lupin Diagnostics Limited is a wholly owned subsidiary of Lupin Limited. Founded in December 2021, the company is headquartered in Mumbai, India and provides comprehensive range of diagnostic services to doctors, patients, and consumers.

The company began its journey by establishing a state-of-the-art 45,000 sq. ft. National Reference Laboratory located in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols. Over 3000 tests including routine and high-end tests are offered under Pathology (molecular diagnostics, cytology, microbiology, serology, hematology, histopathology, immunology, and routine biochemistry).

Currently, LDL operates in West, South, East and Central zones. Experience the best diagnostic experiences with Lupin Diagnostics: https://www.lupindiagnostics.com/

Follow us on:
Facebook:  https://www.facebook.com/lupindiagnostics
Instagram: https://www.instagram.com/lupindiagnostics/
LinkedIn: https://www.linkedin.com/company/lupin-diagnostics/
Twitter: https://twitter.com/LupinDiagnostic
YouTube: https://www.youtube.com/channel/UCbj3DVAmNdbvZayKc2XCIuA

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com